checkAd

     256  0 Kommentare Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis - Seite 3


    VP IR                                                                       Global Head of Communications and Public Affairs
    +1 781 460 1784                                                       +32 473 824 874
                                                                                    
    Sofie Van Gijsel                                                        Anna Gibbins
    Senior Director IR                                                     Senior Director Therapeutic Areas Communications
    +32 485 19 14 15                                                      +44 7717 801900
    ir@glpg.com                                                             communications@glpg.com
    Seite 3 von 4
       



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Galapagos announces that Gilead received a complete response letter for filgotinib for the treatment of moderately to severely active rheumatoid arthritis - Seite 3   Mechelen, Belgium; 19 August 2020, 01.25 CET; regulated information – Galapagos (Euronext & Nasdaq: GLPG) announces today that Gilead Sciences, Inc. (Nasdaq: GILD) received a complete response letter (CRL) from the U.S. Food and Drug …